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ABSTRACT 
 
Objective: There is an increasing evidence that glucagon and growth 
hormone (GH)-insulin-like growth factor (IGF) axis may play an important 
role in glucose metabolism since early stages of glucose intolerance. Carotid 
intima media thickness is a marker for subclinical atherosclerosis. We aimed 
to evaluate glucagon, GH and IGF-1 in prediabetic states and their 
relationship with carotid intima media thickness. 
Methods:  One hundred subjects underwent a 75 gr oral glucose tolerance 
test and were divided into 4 groups according to their state of glucose 
tolerance: (i) normal glucose tolerance (NGT)/Controls (n=21), (ii) impaired 
glucose tolerance (IGT) (n=35), (iii) impaired fasting glucose (IFG) (n=22),  (iv) 
type 2 diabetes mellitus (n=22). Insulin, glucagon and GH were measured at 
0, 60 and 120. minutes of OGTT and their area under the curve (AUC) were 
calculated. Fasting IGF-1 levels and carotid intima media thickness were 
determined in all participants.  
Results: AUC for Glucagon was significantly higher in subjects with IGT, IFG 
and type 2 diabetes mellitus compared to NGT subjects. AUC for GH was 
significantly higher in subjects with IFG compared to subjects with IGT, type 2 
diabetes mellitus and NGT. Plasma IGF-1 levels were significantly lower in 
subjects with abnormal glucose tolerance. CIMT was significantly higher in 
IFG group and CIMT was found to be negatively correlated with IGF-1 levels 
in subjects with IFG.  
Conclusion:  There are pathological alterations of glucagon, GH-IGF-1 and 
insulin in prediabetic stages. Among these alterations insulin resistance and 
IGF-1 are associated with CIMT. Further studies needed to investigate the 
role of treatments targeting insulin sensitivity will have an impact on the 
association between insulin and early atherogenesis 
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ÖZET  
 
Amaç: Glukagonun ve Büyüme Hormonu-İnsülin benzeri büyüme faktörü-1 
(IGF-1) aksının glukoz intoleransının erken evrelerinde itibaren glukoz 
metabolizmasında önemli rollere sahip olduklarını gösteren çalışmalar 
giderek artmaktadır. Karotis intima media kalınlığı subklinik aterosklerozun 
önemli bir belirtecidir. Bu çalışmanın amacı prediyabetik hastalarda 
glukagon, Büyüme hormonu ve IGF-1 düzeyleri ile karotis intima media 
kalınlığı arasındaki ilişkiyi değerlendirmektir.  
Yöntem: Çalışmaya dahil edilen 100 hastaya 75 gr oral glukoz tolerans testi 
yapıldı ve sonuçlara göre hastalar dört gruba ayrıldı: (i) normal glukoz 
toleransı (NGT)/kontrol (n=21), (ii) Bozulmuş glukoz toleransı (BGT) (n=35), 
(iii) Bozulmuş açlık Glukozu (BAG) (n=22), (iv) tip 2 diabetes mellitus (n=22). 
Test sırasında 0,60 ve 120. Dakikalarda insülin, glukagon ve BH düzeyleri ve 0. 
dakikada IGF-1 düzeyi ölçüldü. İnsülin, glukagon ve BH için Eğri altında kalan 
alan hesaplandı. Hastaların karotis intima media kalınlıkları değerlendirildi.  
 Bulgular: Glukagon için hesaplanan eğri altında kalan alan glukoz intoleransı 
olan ve diyabetik hastalarda kontrol grubuna göre anlamlı yüksek bulundu. 
Büyüme hormonu için hesaplanan eğri altında kalan alan bozulmuş açlık 
glukozu olan hastalarda diğer gruplara göre anlamlı yüksek bulundu.  
Anormal glukoz toleransı olan hastalarda plazma IGF-1 düzeyleri kontrol 
grubuna anlamlı düşük bulundu. Karotis İntima media kalınlığı bozulmuş açlık 
glukozu olan hastalarda diğer gruplara göre anlamlı yüksek sapatndı ve bu 
hastalarda karotis intima media kalınlığının plazma IGF-1 düzeyleri ile negatif 
korelasyon gösterdiği görüldü.  
Sonuç: Prediyabetik dönemde de glukagon, büyüme hormonu, IGF-1 ve 
insülin düzeylerinde patolojik değişikilikler olur. Bu değişikliklerden IGF-1 ve 
insülin direnci karotis intima media kalınlığı ile ilişkilidir. İnsülin direncinin 
tedavisi ile insülin ve erken aterogenez arasındaki ilişkiye etkisini araştıran 
ileri çalışmalara ihtiyaç vardır.  
 
Anahtar Sözcükler: Glukoz İntoleransı, İnsülin benzeri Büyüme faktörü-1, 
Karotis intima media kalınlığı, insülin direnci 
 
Geliş Tarihi: 19.07.2016                  Kabul Tarihi: 07.11.2016 
 
 
 
 
 
 
 
 
22 Original Investigation / Özgün Araştırma 
 
 
 
INTRODUCTION 
 
Type 2 Diabetes Mellitus (DM) is a heterogeneous syndrome with 
complex underlying pathophysiology, which involves concomitant 
impairment of insulin action and insulin secretion (1). There is growing 
evidence that type 2 diabetes mellitus may not be merely a beta cell 
dysfunction but also develops as a result of failure of all endocrine pancreas 
and dysregulation of other associated hormones. Growth hormone (GH), 
insulin-like growth factor-I (IGF-I) and glucagon may have roles in glucose 
homeostasis and in pathogenesis of type 2 diabetes mellitus (2,3).  It is 
suggested that alterations of insulin, glucagon and IGF-1 begin in prediabetic 
stages.  
Type 2 DM is associated with increased cardivascular morbidity and 
mortality(4). Impaired fasting Glucose (IFG) and impaired glucose tolerance 
(IGT) are also risk factors for cardiovascular events(5,6). Carotid intima media 
thickness (CMIT), a marker of subclinical atherogenesis and a predictor of 
cardiovascular events is increased in both diabetes and prediabetic stages. 
Beta cell dysfunction and insulin resistance is related with increased CMIT 
however little is known about the relationship between CMIT and glucagon 
and GH-IGF-1 axis.  
In this study, we aimed to evaluate the alterations of insulin, glucagon 
and GH-IGF-1 axis in prediabetes and the relationship between these 
alterations and CMIT in prediabetes and DM.  
 
MATERIAL and METHODS 
 
Patient Population  
A total of 100 subjects (83 females, 17 males; age range: 35-60 years) 
were included in the study. Subjects were recruited from outpatient clinics of 
Ankara University Hospital. All of the subjects were free of cardiovascular, 
pulmonary, renal, hepatic, or other major organ system disease as 
determined by history, physical examination, and routine laboratory tests. 
Patients treated with any drugs that might interfere with glucose metabolism 
were excluded from the study. The purpose and potential risks involved in 
the study were carefully explained to all subjects before obtaining their 
written voluntary consent. The study protocol was reviewed and approved 
by the Institutional Ethic Committee of the Ankara University.  The study was 
conducted according to the declaration of Helsinki. 
The demographic data and the anthropometric measures were obtained 
from all subjects. Body mass index (BMI) was calculated as weight in 
kilograms divided by the height in meters squared.  Waist and hip 
circumferences were measured as the subjects standing. Blood pressure was 
measured twice in a sitting position after 15 minutes rest and the mean of 
two measurements was considered as the participant’s blood pressure. 
Mean arterial pressure (MAP) was calculated with the use of the following 
formula: MAP =  (2 ×DBP + SBP) / 3. 
 
Measurement of biochemical parameters 
All subjects participated in the study underwent 75 gr oral glucose 
tolerance test (OGTT).  Based on the results of OGTT, the subjects were 
divided into four groups according to American Diabetes Association (ADA) 
recommendations 7: (i) Normal Glucose Tolerance (NGT) (served as the 
control group in this study) (n=21), (ii) Impaired Fasting Glucose (IFG) (n=22), 
(iii) Impaired Glucose Tolerance (IGT) (n=35) and (iv) type 2 diabetes mellitus 
(n=22). Before the OGTT, a small polyethylene catheter was placed into an 
antecubital vein and blood samples were collected at 0, 60, and 120 minutes 
for the measurement of plasma glucose, insulin, glucagon and GH 
concentrations. Fasting venous blood samples were also obtained for 
measurement of serum lipids and IGF-1.  Samples for analysis of glucagon, 
GH and IGF-1 were centrifuged immediately and were stored at -20°C for 
further analysis. Plasma glucose concentration was determined by the 
glucose hexokinase method (Roche Diagnostics). Plasma glucagon levels 
were measured by a radioimmunoassay (Linco Research, St Louis, MO). 
Plasma insulin, GH and IGF-1 levels were measured by double 
immunoradiometric assay using reagents from Immunotech (Immunotech, 
Prague, Czech Republic). The lipid parameters (total cholesterol, HDL 
cholesterol, triglycerides) were measured by standardized methods using 
autoanalysers. LDL cholesterol levels were calculated according to the 
formula described by Friedewalds et al 8. Insulin resistance was estimated by 
using Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), 
calculated from fasting glucose and insulin concentrations according to 
following formula: HOMA-IR=(glucose [mg/dl] x insulin[mU/l])/405 9 . 
 
Measurement of Carotid Intima Media Thickness 
Carotid Intima Media Thickness (CIMT) was evaluated by a single 
operator using General Electric Logic 400 Doppler Ultrasound machine and a 
12 MHz linear probe. Subjects were examined in the supine position. Each 
scan of the common carotid artery began just above the clavicle, and the 
transducer was moved cephalad through the bifurcation and along the 
internal carotid artery. The near and distant walls of the common carotid 
artery, the carotid bulb, and the internal carotid artery were scanned for the 
presence of atherosclerotic plaques. Three segments were identified on each 
side: 1.0 centimeters (cm) distal to the common carotid artery proximal to 
the bifurcation, the bifurcation itself and 1.0 cm proximal to the internal 
carotid artery. At each of the three segments, for distant walls in the left and 
right carotid arteries, intima-media thickness was defined as the distance 
between the leading edge of the lumen-intima interface and the leading 
edge of the media-adventitia interface. Maximum thickness of the wall was 
calculated at each side. The reported CIMT for each subject is the average of 
these 10 measurements of distant walls (5 measurements from the right and 
5 from the left carotid artery). The investigator (RE) performed all the 
ultrasonographic examinations blinded to the knowledge of the group the 
subjects belonged.  
 
Statistical Analysis 
All analyses were performed using SPSS software program version 11.5 
for windows. Continuous variables are expressed as means ± SD, non-
normally distributed variables are expressed as median (ranges). The ANOVA 
test was applied for normally distributed continuous data and the Kruskal 
Wallis test was applied to non-normally distributed continuous data. In case 
of p<0.05 between groups, multiple comparison test was used. The Chi 
Square test was performed for categorical data. The values of the area under 
the concentration-time curve for insulin, glucagon and GH were calculated by 
means of trapezoidal rule. For all analyses, a p<0.05 value was considered to 
be statistically significant.  
 
RESULTS 
 
The groups were similar for age, sex, BMI, waist circumference and 
mean BP (Table 1). There were no significant differences among groups in 
terms of mean serum levels of Total Cholesterol, LDL Cholesterol, HDL 
Cholesterol and triglycerides (Table 1). HOMA-IR was significantly higher in 
subjects with IFG, IGT and type 2 diabetes mellitus compared to control 
group (p<0.01) (Table 1).  
The values of area under the concentration-time curve for insulin, 
glucagon and GH between time 0 and 120 were calculated. Plasma insulin 
excursion after glucose load in subjects and area under the curve (AUC) 
values are shown in Figure 1. Area under the curve calculated for insulin was 
significantly higher in subjects with IFG compared to IGT (p=0.03), type 2 
diabetes mellitus (p=0.01) and control group (p=0.002). There was a 
significant difference between subjects with IGT and NGT (p=0.03) while 
there was no difference between diabetic subjects and NGT (p=0.515). Area 
under the curve calculated for glucagon was significantly higher in subjects 
with IGT (p<0.001), IFG (p<0.001) and type 2 diabetes mellitus (p=0.003) 
when compared with NGT subjects. There was no difference between IGT, 
IFG and diabetic group (Figure 1). Area under curve calculated for GH was 
significantly higher in subjects with IFG compared to subjects with IGT 
(p=0.018), type 2 diabetes mellitus (p=0.014) and NGT (p=0.004) (Figure 1). 
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Table 1 Anthropometric and biochemical characteristics of participants 
 
 IGT 
(n=35) 
IFG 
(n=22) 
T2DM 
(n=22) 
Control 
(n=21) 
p 
Age (yrs) † 51.3±6.9 53.9±8.4 53.7±7.2 48.8±7.6 0.065 
Sex(F/M) 30/5 19/3 16/6 18/3 0.927 
BMI (kg/m2) † 31.0±0.6 33.9±1.9 31.3±1.2 30.5±1.2 0.271 
Waist Circumference(cm) † 101.6±10.7 107.6±16.6 102.5±11.1 99.5±15.4 0.215 
Mean BP (mmHg) † 99.0±12.0 101.3±13.8 93.0±9.0 94.0±13.3 0.137 
Glucose (mg/dl) ‡ 93(19) 107(12) 117(12) 91(8) <0.001a 
T. Cholesterol (mg/dl) † 202.4±33.0 211.7±48.1 198.7±42.2 193.3±31.4 0.684 
LDL (mg/dl) † 121.6±24.9 128.6±40.9 121.1±32.5 116.2±32.5 0.821 
HDL (mg/dl) † 45.6±9.8 50.3±9.7 47.7±9.8 50.9±14.3 0.313 
Triglycerides (mg/dl) † 179.9±90.8 166.6±74.7 148.7±70.8 130.6±66.4 0.091 
IGF-1 (ng/ml) ‡ 103(91) 86 (50) 107 (70) 182 (177) 0.020a 
HOMA-IR‡ 3.4(3.1) 4.1(2.7) 3.6(3.5) 2.1(2.0) 0.002a 
CIMT‡ 0.73(0.11) 0.81(0.14) 0.76(0.14) 0.69(0.10) 0.003b 
Insulin (µU/ml) ‡ 14.5 (13.4) 16.1 (12.8) 12.7 (12.4) 9.3 (10.3) 0.065 
Glukagon (pg/ml) ‡ 74.5 (26.5) 69.0 (19.0) 64.5 (11.5) 52 (12.0) 0.005a 
GH (ng/ml) ‡ 0.13 (0.21) 0.27 (0.28) 0.13 (0.15) 0.10 (0.34) 0.061 
† Data are mean±SD 
‡ Date are median (interquarƟl range) 
aControl vs IGT.IFG and T2DM 
bControl vs IFG 
BP:Blood Pressure. IGT: Impaired Glucose Tolerance. IFG:Impaired Fasting Glucose. T2DM: Type 2 Diabetes Mellitus LDL: Low Density Lipoprotein. HDL: High Density 
Lipoprotein CRP:C-Reactive Protein. HOMA-IR: Homeostasis Model Assessment for Insulin Resistance CMIT: Carotid Intima Media Thickness 
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Figure 1. Plasma Insulin (A), Glucagon (B) and Growth Hormone (C) excursion after oral glucose load and area under curve graphics. *p<0,05 
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Median plasma IGF-1 level was 103 ng/ml (91) for IGT group, 86 ng/ml 
(50) for IFG group, 107 ng/ml (70) for type 2 diabetes mellitus group, and 182 
ng/ml (177) for control group. Plasma IGF-1 levels were significantly lower 
(p=0.020) in subjects those with abnormal glucose tolerance compared to 
subjects in control group. 
Median CIMT was 0.73 (0.11) mm for IGT group, 0.81 (0.14) mm for IFG 
group, 0.76 (0.14) mm for type 2 diabetes mellitus group and 0.69 (0.10) mm 
for control group. While CIMT was significantly higher in subjects with IFG 
compared to control group (p=0.003), there was no difference in CIMT 
among subjects with IGT, control and type 2 diabetes mellitus.  There was a 
positive correlation between CMIT and glucose (r=0.304; p=0.005) and 
HOMA-IR (r=0.308;p=0.005) and a negative correlation between IGF-1 and 
CMIT (r=-0.330; p=0.003) among all subjects. There was a significant negative 
correlation between IGF-1 levels and CIMT in subjects with IFG, IGT and DM  
(p=0.01 r=-0.332). CMIT is not correlated with AUC Insulin (r=0.167;p=0.138); 
AUC Glucagon (r=0.160;p=0.168) and AUC GH (r=0.124;p=0.265).  
 
DISCUSSION 
 
In this study, subjects with both impaired glucose tolerance, impaired 
fasting glucose and type 2 diabetes mellitus were relatively 
hyperglucagonemic compared to normal glucose tolerant subjects. Plasma 
glucagon concentrations are inappropriately elevated in diabetic individuals, 
and α-cell suppression by hyperglycaemia is blunted (10). Although 
dysregulated glucagon secretion and elevated glucagon levels are known to 
be associated with high blood glucose in type 2 diabetes mellitus(11), these 
conditions are usually considered a consequence instead of a cause of 
diabetes, and it remains controversial whether glucagon, plays an active role 
in diabetes development (12). Our data suggest that combined decreased 
insulin secretion and increased insulin resistance may not be sufficient to 
induce hyperglycaemia without dysregulated glucagon secretion, and thus 
reveal a previously underappreciated role of the regulation of glucagon 
secretion in the development of diabetes. Increased glucagon secretion may 
also promote diabetes development at prediabetic stages such as impaired 
glucose tolerance and impaired fasting glucose. There was no significant 
correlation between AUC glucagon and CIMT in our study. There is little 
known about the relationship between glucagon and atherosclerosis in 
diabetic patients. However studies suggest that Glucagon like peptide-1 
analogs which suppresses glucagon secretion have cardioprotective role 
independent of their glucose lowering effects(13). Further studies needed in 
this era.  
In our study, we showed a negative correlation between serum IGF-1 
levels and CIMT and positive correlation between HOMA-IR and CIMT among 
all participants. Observational studies investigating associations between 
IGF1 and its binding proteins (IGFBPs) with CIMT have yielded inconsistent 
results. Both increased and decreased levels of IGF-1 was found to be 
associated with thickening of carotid intima media (14-18).  Previous analysis 
by Martin et al. revealed no association between IGF-1 and IMT(19). There 
are IGF-1 receptors on human endothelial cells and IGF-1 is potent mitogen 
and antiapoptotic factor for vascular smooth muscles(20). In early stages of 
atherosclerosis decrease of IGF-1 levels might be beneficial but in advanced 
stages IGF-1 has an important role on plaque stability(21). This dual role of 
IGF-1 on atherosclerosis may explain the negative correlation between CIMT 
and IGF-1 in our study.  All participants in our study were obese. Obesity is 
characterized with low IGF-1 levels(22). This might be another explanation of 
low IGF-1 levels of our patients.  
One important result of our study was positive correlation between 
HOMA-IR and CIMT. This is an agreement with a recent study that has shown 
that patients with higher CIMT had lower insulin sensitivity(23). Roussel et al. 
showed that insulin secretion is associated with early atherosclerosis in non 
diabetic individuals(24). Insulin receptors are expressed both on endothelial 
cells and vascular smooth muscle. Insulin signaling pathways in vascular 
endothelium stimulates vasodilatator NO and also stimulates vasoconstrictor 
ET-1(25). Inappropriate insulin secretion and action may triggers an 
imbalance between these signaling pathways in the endothelium and may 
cause subclinical atherosclerosis.  
Plasma IGF-1 levels were significantly lower in subjects those with 
abnormal glucose tolerance compared to subjects with NGT.  Our data is 
consistent with a previous study by Sesti et al. who found a significant 
positive correlation between insulin sensitivity and endogenous IGF-I 
concentration among patients with varying degrees of glucose 
intolerance(26).  There is considerable evidence suggesting that IGF-1 has 
insulin-like effects on peripheral uptake of glucose and fatty acids(27). 
Obesity, an insulin resistance state and a strong risk factor for type 2 DM, 
was associated with altered IGF-1 levels. Taken together with our present 
data suggests that IGF-1 may have role in pathogenesis of type 2 DM.  
Area under curve calculated for GH was significantly higher in subjects 
with IFG compared to subjects with IGT, type 2 diabetes mellitus and NGT. 
We also found that the patients with IGT had the lowest IGF-1 levels 
compared to other groups. This may be the result of inadequate negative 
feedback of low plasma IGF-I concentrations at the level of the hypothalamus 
and/or pituitary, thus resulting in growth hormone (GH) hypersecretion and 
a decrease in insulin sensitivity.   
Our study has some limitations. We only measured total IGF-1 and not 
the free fraction, which is the form that interacts with IGF-1 receptor and is 
responsible for the peripheral effect. Relatively small sample size and cross 
sectional design are also the limitations of the study.  
As a conclusion, there are pathological alterations of glucagon, GH-IGF-1 
and insulin in prediabetic stages. Among these alterations insulin resistance 
and IGF-1 are associated with CIMT. Further studies needed to investigate 
the role of treatments targeting insulin sensitivity will have an impact on this 
association between insulin and early atherogenesis. 
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